Casein Kinase 1 delta/epsilon inhibitors: A new class of anti-asthma agents?

Abstract

Asthma affects more than 10% of the population. Severe steroid-dependent asthma occurs in ~5% of patients but is estimated to account for 50% of the cost. The only mechanistically new therapies for asthma in the past 30 years, target so-called T2 asthma, which is driven by T helper 2 -type cytokines, with antibodies targeting interleukin-5 or its receptor. These biological therapies do not meet the needs of the majority of the severe steroid dependent asthma subgroup. Our efforts have been directed to identifying pathways which underlie the remodelling response, which is prominent in severe asthma. This focus on structural cell types within the airway wall has identified that the mechanical ..